https://doi.org/10.1016/s0140-6736(21)00149-5
S
Sharon Dorgan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
28
Papers
2.3K
Citations
9
h-index
9
i10-index
Sharon Dorgan is an academic researcher. The author has contributed to research in topics: COVID-19 Clinical Research Studies & Peripheral Artery Disease Management & SARS-CoV-2 and COVID-19 Research. The author has an h-index of 9, co-authored 24 publications.
ORCID: 0009-0006-0023-6701Papers by this author
worksAzithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · The Lancet · 556 citations
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · The Lancet · 516 citations
https://doi.org/10.1016/s0140-6736(21)00897-7
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · The Lancet · 320 citations
https://doi.org/10.1016/s0140-6736(22)01109-6
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · The Lancet · 289 citations
https://doi.org/10.1016/s0140-6736(21)01825-0
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · The Lancet Diabetes & Endocrinology · 36 citations
https://doi.org/10.1016/s2213-8587(23)00253-x
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · The Lancet Child & Adolescent Health · 33 citations
https://doi.org/10.1016/s2352-4642(23)00316-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat